OctoPlus N.V. has signed a feasibility agreement with a leading generics company to develop a generic formulation of an existing injectable specialty pharmaceutical product. OctoPlus will develop a generic copy the injectable specialty pharmaceutical for small-scale production. If the project is successful, the contract may expand to a full process development and manufacturing agreement. Financial terms were not disclosed. Jan Egberts, chief executive officer of OctoPlus, said, “Developm...